Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amarnath Sharma

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumorsHenry C Pitot, Alex A Adjei, Joel M Reid, et al.
Targeted Oncology|June 24, 2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Targeted Oncology|August 1, 2022
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumorsHenry C Pitot, Alex A Adjei, Joel M Reid, et al.
Targeted Oncology|June 24, 2022
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Targeted Oncology|August 1, 2022
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2006
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionLarry J Schaaf, Lisa A Hammond, Stuart J Tipping, et al.
Pageof 5